29 September 2016 - The Institute for Clinical and Economic Review has released an evidence report assessing the comparative clinical effectiveness and value of treatments for non-small cell lung cancer.

A draft version of this report was open for a four-week public comment period. The updated Evidence Report reflects changes made based on comments received from patient groups, clinicians, the manufacturers of the drugs, and other stakeholders.

This assessment evaluates the health and economic outcomes of certain tyrosine kinase inhibitors (TKIs) and programmed death 1 (PD-1) agents in the treatment of advanced non-small cell lung cancer (NSCLC). The effects of both classes of agents are evaluated in EGFR-positive (EGFR+) NSCLC, and PD-1 agents are evaluated in NSCLC without a driver mutation (EGFR-).

A key goal of ICER's reports is to ensure that patients, providers, insurers, and policymakers have the information they need to support efforts to improve the quality and value of care. The report provides analyses of the clinical effectiveness and comparative value (including long-term cost-effectiveness and potential budget impact) of the drugs under study.

Read ICER's evidence report